Developer docs
API playgroundTry for free, no card

Search company profiles

Causaly

Full company profile

uuid0000spu

Namestring
Causaly
Legal namestring
Causaly Ltd
Websiteurl
causaly.com
Company typeenum
Private
Founded yearint
2018
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biomedical knowledge graph, drug discovery AI, scientific literature analysis, biomedical research platform, life sciences agentic AI
Industry3 codes
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAJAC
Scientific Data Management & Data Platforms (SDMS/Data Lakehouse for R&D)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAJAF
Clinical & Translational Informatics (Clinical Data Integration/Real-World Data for R&D)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Software Publishers5132
  • Research and Development in the Physical, Engineering, and Life Sciences54171
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Services-Prepackaged Software7372
Product category
Life Sciences AI Platform (Drug Discovery & Biomedical Research)
Social media profiles3 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Enterprise SaaS Subscription
TypeSubscription Recurring
Description

Causaly operates on a subscription-based model targeting enterprise biopharmaceutical companies. The platform is sold as an enterprise license with annual or multi-year contracts, with pricing based on seat count and feature access. Professional services for implementation and workflow configuration are offered as additional services.

causaly.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure
Pricing details1 tier
1Enterprise platform with configurable modules and workflow capabilities
ModelSubscriptionBilling cadenceAnnual
Notes

Quote-based / Not publicly disclosed. Enterprise contracts typically annual or multi-year with seat-based or value-based pricing.

causaly.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 9 records shown
1Agentic Research
Description

Science-grade AI platform for R&D with multi-autonomous AI agents that plan, research, and synthesize biomedical evidence

causaly.com
+8 more records
Core offering1 text field

Causaly builds and sells an Agentic AI platform for life sciences R&D that combines a proprietary 500-million-fact biomedical knowledge graph with multi-agent AI orchestration to automate target identification, biomarker discovery, disease pathophysiology analysis, indication expansion, and competitive pipeline intelligence. The platform is sold as enterprise SaaS subscriptions to global biopharmaceutical and biotech organizations and delivers cited, evidence-backed outputs with traceability suitable for FDA regulatory submissions. Additional offerings include the Bio Graph API for programmatic access, professional implementation services, and integrated competitive intelligence through Pipeline Graph.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • Target prioritization exercises reduced from 4 weeks to 5 days while preserving full traceability
+5 more records
Product overview1 text field

Causaly is an Agentic AI Platform For Life Sciences that provides a unified platform-plus-modules architecture. The core platform consists of an AI workspace with specialized capabilities: the Knowledge Graph (500M facts, 70M directional relationships), Enterprise Data Fabric, and Scientific Information Retrieval System (SIRS). Key products include: Scientific Workflows (end-to-end autonomous AI workflows), Agentic Research (multi-agent AI system with Planner/Executor/Principal Investigator), Discover (AI-powered literature analysis with agentic AI), Bio Graph (biomedical knowledge visualization), Bio Graph API (programmatic access), Pipeline Graph (competitive intelligence for drug pipelines), and Generative AI Copilot (natural language research assistant). The platform is purpose-built for scientific intelligence and execution, enabling target identification, biomarker discovery, disease pathophysiology analysis, and indication expansion across the pharmaceutical R&D pipeline.

Product and service8 records
1Scientific Workflows
CategoryScientific Workflow Automation
Description

Solution that converts biopharma research methods into autonomous, repeatable AI workflows run by multi-agent orchestration. Produces structured, evidence-backed, decision-ready outputs including target assessments, indication exploration reports, claims substantiation packages, and safety dossiers. Sold to life sciences R&D organizations.

2Agentic Research
CategoryAgentic AI Research Platform
Description

Science-grade AI platform for R&D in which domain-specialized AI agents plan, search, reason, and conclude behind a clean chat interface. Multi-agent orchestration coordinates a Planner, Executor, and Principal Investigator to accelerate hypothesis-to-evidence-backed decision workflows. Sold to life sciences R&D organizations.

3Discover
CategoryBiomedical Literature Research Application
Description

AI-powered research application that enables scientists to answer complex biomedical questions faster and more accurately across broader sources. Features automatic generation of detailed reports and integration with external resources such as the Human Protein Atlas. Sold to life sciences R&D teams.

4Bio Graph
CategoryBiomedical Knowledge Graph
Description

High-precision biomedical knowledge graph containing 500+ million curated data points and 70 million directional relationships across 8 relationship types. Enables visualization of pathways and mechanisms, uncovers non-obvious hypotheses, and supports prioritization of actionable targets and biomarkers. Sold to life sciences organizations.

5Bio Graph API
CategoryKnowledge Graph API
Description

API offering that enables customers to bring Causaly's life sciences knowledge graph in-house, allowing integration of biomedical knowledge into internal systems and workflows. Sold to enterprises that require programmatic access.

6Pipeline Graph
CategoryCompetitive Intelligence Platform
Description

AI-driven competitive intelligence platform for early-stage drug discovery that integrates over 100,000 pipeline drugs, 60,000 research programs, and 15,000 organizations into a dual knowledge graph architecture combined with biological research data. Includes an AI copilot for natural-language queries. Sold to life sciences competitive intelligence teams.

7Generative AI Copilot (Causaly Copilot)
CategoryGenerative AI Copilot
Description

The first AI copilot purpose-built for scientists, enabling natural language research queries and AI-powered literature analysis within the Causaly platform. Sold to life sciences research organizations.

8Microsoft Discovery Integration
CategoryIntegrated AI Research Workflow
Description

Integrated solution combining Microsoft Discovery's enterprise-scale analytics, prediction, and simulation capabilities with Causaly's knowledge-graph reasoning into a unified workflow for life sciences R&D. Sold to biopharma customers for target identification, biomarker strategy, and in silico prediction.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-06-02
Description

Collaboration announced at Microsoft Build 2026 integrating Microsoft Discovery's enterprise-scale analytics, prediction, and simulation capabilities with Causaly's knowledge-graph reasoning into a unified workflow for life sciences R&D. The combined solution targets biopharma organizations accelerating target identification, biomarker strategy, and in silico prediction while meeting scientific and regulatory standards. Enables R&D teams to move from computational signals to cited, defensible decisions in a governed environment.

Strategic tierNotableTypeStrategic or Co-development PartnerAnnounced on2020-04-21
Description

Partnership to accelerate COVID-19 pandemic research. UCL researchers used Causaly to work on COVID-19 projects including therapeutics development, diagnostic approaches, epidemiological models, mental health strategies, and healthcare system logistics. Causaly provided access to its biomedical literature platform mapping molecular pathways and potential treatment options.

Strategic tierSupportingTypeTechnology or IntegrationAnnounced on2019-11-19
Description

Content partnership for accessing biomedical literature and publications within the Causaly platform.

4Wiley
Strategic tierSupportingTypeTechnology or IntegrationAnnounced on2019-11-19
Description

Content partnership for accessing scientific publications within the Causaly platform for life sciences research.

causaly.com
Strategic tierSupportingTypeTechnology or IntegrationAnnounced on2019-11-19
Description

Content partnership for accessing scientific publications within the Causaly platform.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight2 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Insitro applies ML to large-scale biological data generated in-house to discover and develop therapeutics. Like Causaly, it targets the intersection of AI and life sciences R&D for top pharma, though Insitro focuses on data-generation plus ML whereas Causaly focuses on biomedical knowledge representation and reasoning.

TypeBroad incumbent
Description

Schrödinger provides computational chemistry and physics-based simulation software widely used in pharma drug discovery. It overlaps with Causaly in serving pharma R&D with scientific software, but focuses on molecular simulation and materials science rather than literature/knowledge graph reasoning.

TypeDirect peer
Description

Benchling is a cloud platform for life sciences R&D, offering lab notebooks, registry, and workflow tools used by top pharma and biotech. Both companies compete for the same biopharma R&D IT wallet, with Causaly differentiating on AI-driven literature/evidence synthesis and Benchling on experimental data capture and lab workflows.

TypeOthers
Description

Clarivate offers scientific intelligence and research databases such as Cortellis and Web of Science, used by pharma for competitive intelligence and drug pipeline analysis. It is thematically adjacent to Causaly's Pipeline Graph and competitive intelligence modules, though it is primarily a data vendor rather than an AI agent platform.

TypeDirect peer
Description

Exscientia was a pioneer in AI-driven small molecule drug design using active learning and automated synthesis (now merged with Recursion). It overlaps with Causaly as an AI-for-drug-discovery platform serving pharma partners, though its emphasis is generative chemistry and design-make-test cycles.

6Elsevier (RELX)
TypeOthers
Description

Elsevier owns major biomedical literature databases (Embase, Scopus, ScienceDirect) and Reaxys for chemistry, forming the upstream content backbone that life sciences AI platforms including Causaly integrate. It is a key content partner/competitor depending on whether Elsevier expands into AI-driven reasoning on top of its own data.

TypeDirect peer
Description

Owkin is an AI biotech platform that connects federated learning, multimodal patient data, and pharma partnerships to accelerate research and clinical trials. It overlaps with Causaly in using AI to unlock biomedical evidence for pharma R&D and clinical development, with a stronger emphasis on patient data and clinical trials.

TypeBroad incumbent
Description

Palantir's Foundry platform is used by several large pharma and biotech companies for data integration and analytics across R&D and operations. It is a broader data and analytics incumbent that could compete with or complement Causaly's Enterprise Data Fabric layer inside pharma IT environments.

TypeDirect peer
Description

Recursion is an AI-native drug discovery company combining its own high-throughput wet-lab data with ML models to build a 'map of biology.' It overlaps with Causaly's mission to use AI for life sciences, with Recursion emphasizing proprietary experimental data and internal pipelines versus Causaly's literature-and-knowledge-graph approach.

10Isomorphic Labs
TypeDirect peer
Description

Alphabet's Isomorphic Labs applies DeepMind's AI to drug discovery, combining protein structure prediction and computational chemistry. It is a deep-pocketed competitor pursuing the same 'AI for life sciences R&D' thesis as Causaly, though more weighted toward structural biology and in silico molecule design.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers11 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
Yes

Docs URL, Description

Integration2 records

Each record includes

Title, Type, Description, Source

AI capability9 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Causaly

Life Sciences AI Platform (Drug Discovery & Biomedical Research)causaly.com

Causaly firmographics

Firmographics
Name
Causaly
Legal name
Causaly Ltd
Website
https://causaly.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
101–250 employees
Ownership category
akta.pro rank

Causaly industry classification

Industry
Product category
Life Sciences AI Platform (Drug Discovery & Biomedical Research)
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Software Publishers (5132), Research and Development in the Physical, Engineering, and Life Sciences (54171)
SIC
Services-Commercial Physical & Biological Research (8731), Services-Prepackaged Software (7372)
akta.pro industry
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAJAC
Scientific Data Management & Data Platforms (SDMS/Data Lakehouse for R&D)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAJAF
Clinical & Translational Informatics (Clinical Data Integration/Real-World Data for R&D)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)

Keywords

  • Biomedical knowledge graph
  • Drug discovery AI
  • Scientific literature analysis
  • Biomedical research platform
  • Life sciences agentic AI

Where Causaly is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Offices2 records

Markets served

Causaly business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. Enterprise SaaS Subscription: Causaly operates on a subscription-based model targeting enterprise biopharmaceutical companies. The platform is sold as an enterprise license with annual or multi-year contracts, with pricing based on seat count and feature access. Professional services for implementation and workflow configuration are offered as additional services.

Pricing tiers

ModelBillingPrice
SubscriptionAnnualEnterprise platform with configurable modules and workflow capabilities

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Causaly product offering

Product offering

Core offering

Causaly builds and sells an Agentic AI platform for life sciences R&D that combines a proprietary 500-million-fact biomedical knowledge graph with multi-agent AI orchestration to automate target identification, biomarker discovery, disease pathophysiology analysis, indication expansion, and competitive pipeline intelligence. The platform is sold as enterprise SaaS subscriptions to global biopharmaceutical and biotech organizations and delivers cited, evidence-backed outputs with traceability suitable for FDA regulatory submissions. Additional offerings include the Bio Graph API for programmatic access, professional implementation services, and integrated competitive intelligence through Pipeline Graph.

Product overview

Causaly is an Agentic AI Platform For Life Sciences that provides a unified platform-plus-modules architecture. The core platform consists of an AI workspace with specialized capabilities: the Knowledge Graph (500M facts, 70M directional relationships), Enterprise Data Fabric, and Scientific Information Retrieval System (SIRS). Key products include: Scientific Workflows (end-to-end autonomous AI workflows), Agentic Research (multi-agent AI system with Planner/Executor/Principal Investigator), Discover (AI-powered literature analysis with agentic AI), Bio Graph (biomedical knowledge visualization), Bio Graph API (programmatic access), Pipeline Graph (competitive intelligence for drug pipelines), and Generative AI Copilot (natural language research assistant). The platform is purpose-built for scientific intelligence and execution, enabling target identification, biomarker discovery, disease pathophysiology analysis, and indication expansion across the pharmaceutical R&D pipeline.

Differentiator

Problem solved

Functional benefit

Brands

  • Agentic Research: Science-grade AI platform for R&D with multi-autonomous AI agents that plan, research, and synthesize biomedical evidence
  • Bio Graph
  • Pipeline Graph
  • Discover
  • Scientific Workflows
  • Bio Graph API
  • Generative AI Copilot
  • Enterprise Data Fabric
  • Scientific RAG

Products and services

  • Scientific Workflows Solution that converts biopharma research methods into autonomous, repeatable AI workflows run by multi-agent orchestration. Produces structured, evidence-backed, decision-ready outputs including target assessments, indication exploration reports, claims substantiation packages, and safety dossiers. Sold to life sciences R&D organizations.
  • Agentic Research Science-grade AI platform for R&D in which domain-specialized AI agents plan, search, reason, and conclude behind a clean chat interface. Multi-agent orchestration coordinates a Planner, Executor, and Principal Investigator to accelerate hypothesis-to-evidence-backed decision workflows. Sold to life sciences R&D organizations.
  • Discover AI-powered research application that enables scientists to answer complex biomedical questions faster and more accurately across broader sources. Features automatic generation of detailed reports and integration with external resources such as the Human Protein Atlas. Sold to life sciences R&D teams.
  • Bio Graph High-precision biomedical knowledge graph containing 500+ million curated data points and 70 million directional relationships across 8 relationship types. Enables visualization of pathways and mechanisms, uncovers non-obvious hypotheses, and supports prioritization of actionable targets and biomarkers. Sold to life sciences organizations.
  • Bio Graph API API offering that enables customers to bring Causaly's life sciences knowledge graph in-house, allowing integration of biomedical knowledge into internal systems and workflows. Sold to enterprises that require programmatic access.
  • Pipeline Graph AI-driven competitive intelligence platform for early-stage drug discovery that integrates over 100,000 pipeline drugs, 60,000 research programs, and 15,000 organizations into a dual knowledge graph architecture combined with biological research data. Includes an AI copilot for natural-language queries. Sold to life sciences competitive intelligence teams.
  • Generative AI Copilot (Causaly Copilot) The first AI copilot purpose-built for scientists, enabling natural language research queries and AI-powered literature analysis within the Causaly platform. Sold to life sciences research organizations.
  • Microsoft Discovery Integration Integrated solution combining Microsoft Discovery's enterprise-scale analytics, prediction, and simulation capabilities with Causaly's knowledge-graph reasoning into a unified workflow for life sciences R&D. Sold to biopharma customers for target identification, biomarker strategy, and in silico prediction.

Quantifiable outcome

  • Target prioritization exercises reduced from 4 weeks to 5 days while preserving full traceability
  • +5 more outcomes

Companies that use Causaly

Customer profile

Named customers11 records

Segments3 records

Ideal customer profiles2 records

Causaly technology and API

Technology

Technology focussed Yes

API detail

Has API
Yes
API docs
API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability9 records

Feature6 records

Causaly partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core, notable and supporting.

  • MicrosoftcoreTechnology or Integration · 2 June 2026Collaboration announced at Microsoft Build 2026 integrating Microsoft Discovery's enterprise-scale analytics, prediction, and simulation capabilities with Causaly's knowledge-graph reasoning into a unified workflow for life sciences R&D. The combined solution targets biopharma organizations accelerating target identification, biomarker strategy, and in silico prediction while meeting scientific and regulatory standards. Enables R&D teams to move from computational signals to cited, defensible decisions in a governed environment.
  • University College London (UCL)notableStrategic or Co-development Partner · 21 April 2020Partnership to accelerate COVID-19 pandemic research. UCL researchers used Causaly to work on COVID-19 projects including therapeutics development, diagnostic approaches, epidemiological models, mental health strategies, and healthcare system logistics. Causaly provided access to its biomedical literature platform mapping molecular pathways and potential treatment options.
  • Copyright Clearance CentersupportingTechnology or Integration · 19 November 2019Content partnership for accessing biomedical literature and publications within the Causaly platform.
  • WileysupportingTechnology or Integration · 19 November 2019Content partnership for accessing scientific publications within the Causaly platform for life sciences research.
  • SagesupportingTechnology or Integration · 19 November 2019Content partnership for accessing scientific publications within the Causaly platform.

Scale indicators6 records

Recent moves6 records

Expansion highlights2 records

Causaly competitors and assessment

Company assessment

Direct peers

  • Insitro: Insitro applies ML to large-scale biological data generated in-house to discover and develop therapeutics. Like Causaly, it targets the intersection of AI and life sciences R&D for top pharma, though Insitro focuses on data-generation plus ML whereas Causaly focuses on biomedical knowledge representation and reasoning.
  • Benchling: Benchling is a cloud platform for life sciences R&D, offering lab notebooks, registry, and workflow tools used by top pharma and biotech. Both companies compete for the same biopharma R&D IT wallet, with Causaly differentiating on AI-driven literature/evidence synthesis and Benchling on experimental data capture and lab workflows.
  • Exscientia: Exscientia was a pioneer in AI-driven small molecule drug design using active learning and automated synthesis (now merged with Recursion). It overlaps with Causaly as an AI-for-drug-discovery platform serving pharma partners, though its emphasis is generative chemistry and design-make-test cycles.
  • Owkin: Owkin is an AI biotech platform that connects federated learning, multimodal patient data, and pharma partnerships to accelerate research and clinical trials. It overlaps with Causaly in using AI to unlock biomedical evidence for pharma R&D and clinical development, with a stronger emphasis on patient data and clinical trials.
  • Recursion Pharmaceuticals: Recursion is an AI-native drug discovery company combining its own high-throughput wet-lab data with ML models to build a 'map of biology.' It overlaps with Causaly's mission to use AI for life sciences, with Recursion emphasizing proprietary experimental data and internal pipelines versus Causaly's literature-and-knowledge-graph approach.
  • Isomorphic Labs: Alphabet's Isomorphic Labs applies DeepMind's AI to drug discovery, combining protein structure prediction and computational chemistry. It is a deep-pocketed competitor pursuing the same 'AI for life sciences R&D' thesis as Causaly, though more weighted toward structural biology and in silico molecule design.

Broad incumbents

  • Schrödinger: Schrödinger provides computational chemistry and physics-based simulation software widely used in pharma drug discovery. It overlaps with Causaly in serving pharma R&D with scientific software, but focuses on molecular simulation and materials science rather than literature/knowledge graph reasoning.
  • Palantir Technologies: Palantir's Foundry platform is used by several large pharma and biotech companies for data integration and analytics across R&D and operations. It is a broader data and analytics incumbent that could compete with or complement Causaly's Enterprise Data Fabric layer inside pharma IT environments.

Others

  • Clarivate: Clarivate offers scientific intelligence and research databases such as Cortellis and Web of Science, used by pharma for competitive intelligence and drug pipeline analysis. It is thematically adjacent to Causaly's Pipeline Graph and competitive intelligence modules, though it is primarily a data vendor rather than an AI agent platform.
  • Elsevier (RELX): Elsevier owns major biomedical literature databases (Embase, Scopus, ScienceDirect) and Reaxys for chemistry, forming the upstream content backbone that life sciences AI platforms including Causaly integrate. It is a key content partner/competitor depending on whether Elsevier expands into AI-driven reasoning on top of its own data.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Causaly social profiles

Digital presence

Causaly compliance and trust

Trust signal

Compliance1 record

Causaly financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Causaly leadership team

Management profile

Number of profiles

Profiles4 records

Causaly funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Causaly M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Causaly

What does Causaly do?

Causaly builds and sells an Agentic AI platform for life sciences R&D that combines a proprietary 500-million-fact biomedical knowledge graph with multi-agent AI orchestration to automate target identification, biomarker discovery, disease pathophysiology analysis, indication expansion, and competitive pipeline intelligence. The platform is sold as enterprise SaaS subscriptions to global biopharmaceutical and biotech organizations and delivers cited, evidence-backed outputs with traceability suitable for FDA regulatory submissions. Additional offerings include the Bio Graph API for programmatic access, professional implementation services, and integrated competitive intelligence through Pipeline Graph.

Is Causaly a public or private company?

Causaly is a private company. It is classified as venture growth investor backed and is currently operating.

When was Causaly founded?

Causaly was founded in 2018. It employs 101 to 250 people.

Where is Causaly based?

Causaly is headquartered in London, United Kingdom, in the Europe region.

How does Causaly make money?

One revenue line is on record: enterprise SaaS Subscription.

Who are Causaly's main competitors?

Direct peers on record are Insitro, Benchling, Exscientia, Owkin, Recursion Pharmaceuticals and Isomorphic Labs. Broad incumbents are Schrödinger and Palantir Technologies. Others are Clarivate and Elsevier (RELX).

Does Causaly have an API?

Yes. Causaly offers a Bio Graph API that enables users to bring the most powerful life sciences knowledge graph in-house. The API License document is available (Last Updated: December 6, 2023). The platform also supports MCP (Model Context Protocol) frameworks for data integration, as mentioned in the context of agentic AI workflows. Developer documentation is at get.causaly.com/hubfs/Legal/Causlay%20API%20License%20(2023.12.06).pdf.

What industry is Causaly in?

Causaly's product category is Life Sciences AI Platform (Drug Discovery & Biomedical Research). Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAGAJAC, Scientific Data Management & Data Platforms (SDMS/Data Lakehouse for R&D). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Third NewsCausaly Work Revolutionizes Life Sciences Research and Development DecisionsCausaly Work is an AI-driven platform for life sciences R&D that streamlines research and analysis. It uses specialized AI agents to select methodologies and deliver completed outputs, enabling scientists to explore more options and evaluate them based on relevant criteria. The platform aims to accelerate breakthroughs and enhance productivity in research teams.PR NewswireNew Causaly Work Helps Scientists Complete More of the Work Behind R&D Decisions, from Discovery Through Clinical DevelopmentCausaly introduced Causaly Work, an agentic AI platform for life sciences R&D, to help scientists complete work from discovery through clinical development. The platform lets scientists set objectives, and specialized agents select methods and deliver results for review. It aims to help teams make decisions by completing more scientific work.AktienNew Causaly Work Helps Scientists Complete More of the Work Behind R&D Decisions, from Discovery Through Clinical DevelopmentCausaly introduced Causaly Work, an agentic AI platform for life sciences R&D that plans and executes research to support team decisions. It pairs scientific reasoning with a computational layer to produce completed outputs, helping scientists explore more options. CEO Yiannis Kiachopoulos said it widens the set of options and evaluates each one across relevant dimensions.MarTech SeriesCausaly is Now Available in Microsoft CopilotCausaly expanded its collaboration with Microsoft to bring agentic scientific research into Microsoft Copilot, allowing enterprise life sciences R&D to access it within Microsoft 365 workflows. The integration provides evidence-grounded, cited answers from peer-reviewed literature and Causaly's knowledge graphs, extending its prior partnership with Microsoft Discovery.MarketScreenerCausaly Limited and Microsoft Corporation Expand Collaboration to Integrate Causaly into Microsoft CopilotCausaly Limited expanded its collaboration with Microsoft to integrate agentic scientific research into Microsoft Copilot, allowing enterprise life sciences R&D to access Causaly within Microsoft 365 workflows. The integration provides evidence-grounded answers with traceable references to peer-reviewed literature and Causaly's knowledge graphs. This builds on a June 2026 Build announcement that combined Causaly with Microsoft Discovery.PR NewswireCausaly is Now Available in Microsoft CopilotCausaly announced its scientific research platform is now available in Microsoft Copilot, allowing enterprise life sciences R&D to access it within Microsoft 365 workflows. The agent surfaces prior science, reasons over biological mechanisms, and synthesizes evidence into cited answers, with traceable references to peer-reviewed literature and proprietary knowledge graphs. Causaly is available on the Microsoft Marketplace.PR NewswireCausaly and Syneos Health Partner to Raise the Scientific Intensity of Clinical ResearchCausaly and Syneos Health announced a strategic partnership to integrate Causaly's agentic AI platform into Syneos Health's scientific workflows. This collaboration aims to accelerate clinical development by enabling faster, evidence-backed decision-making across therapeutic areas and proposal development. The initiative seeks to raise the scientific intensity of research outputs while maintaining rigor and improving sponsor value.BioSpaceSyneos Health Advances AI-Powered Clinical Ecosystem to Optimize Trial Performance and Speed Decision-MakingSyneos Health announced the continued advancement of its AI ecosystem, embedding AI into clinical development workflows. The approach integrates deep therapeutic expertise and healthcare professional intelligence to anticipate risk earlier and improve study performance. The company emphasizes human oversight and governance for responsible use in regulated environments.Technology RecordFrom discovery to delivery: the life sciences innovation journeyMicrosoft highlights three life sciences startups—Causaly, Biolevate, and Dawn Health—that are deploying AI-powered tools to accelerate innovation across the drug development and patient care value chain. These companies address specific bottlenecks in research discovery, regulatory documentation, and digital patient engagement to improve efficiency and outcomes in the healthcare sector.SelectScienceUniversity College London partners with Causaly to accelerate coronavirus researchUCL academics have partnered with AI technology company Causaly to accelerate COVID-19 research, granting UCL researchers access to Causaly's platform that can analyze 30 million biomedical publications and 170 million cause-and-effect relationships. The collaboration aims to help identify biomarkers, molecular targets, and potential therapeutic agents for COVID-19, as well as support research into diagnostics, epidemiological models, and mental health strategies. The partnership was facilitated through UCL Innovation & Enterprise following discussions that predated the pandemic but gained urgency as COVID-19 escalated.